- Home
- Optimising treatment
Optimising treatment
Revolutionising Thrombosis Treatment in ACS, SSP and AF
- 1.00
Published:
Learning objectives
- Discuss the unmet needs in thrombosis management, MACE burden after ACS, stroke in AF and secondary stroke prevalence and consequences
- Evaluate the current standard of care for the treatment of ACS, SSP and AF and its limitations
- Review guidelines and critique current prescribing practices and the implications of inadequate treatment
- Explain the different strategies for targeting FXI and how FXI inhibition mechanisms differentiate from traditional anticoagulation therapies
- Identify emerging anticoagulant strategies and describe the efficacy and safety data from Phase 2 FXI inhibitor clinical trials as well as ongoing Phase 3 trials and potential place in therapy for ACS, AF and SSP
- Apply evidence-based anticoagulation strategies by optimising treatment decisions and addressing patient-specific risk factors
Achieving Lipid Targets & Managing CV Risk: Reassessing our way with Statins
- 1.00
Published:
Learning objectives
- Recall prevalence of patients who are statin uncontrolled/intolerant
- Define the additive benefit of combination treatment compared with statin intensification
- Name the non-statin LLTs offering proven CV protection
- Identifying patients with indication for novel non-statin therapy
- Initiate lipid-lowering strategies proven to lower future CV events
The Clinical Evidence Behind Pulse Field Ablation
- 1.00
Published:
Learning objectives
- Identify limitations of current ablation technologies
- Recall the advantages of pulse field ablation over other technologies
- Summarise the design, efficacy and safety findings of relevant clinical trial data evaluating the efficacy and safety of pulse field ablation technology
- Compare different PFA systems and emerging technologies
- Evaluate the evolving landscape of pulse field ablation technologies
Examining a Complex Heart Failure Case
- 1.00
Published:
Learning objectives
- Identify individuals likely to have HFpEF from initial presentation
- Refer suspected individuals for specialist assessment
- Initiate GDMT for HF as soon as patients are stable
- Initiate GDMT in HF regardless of EF and phenotype
- Initiate shared decision-making on complex HF patients with other members of the multidisciplinary team including cardiologists, GPs, nephrologists and diabetologists